The Oncology Institute Q2 EPS $(0.19) Misses $(0.17) Estimate, Sales $80.22M Beat $73.79M Estimate
Portfolio Pulse from Benzinga Newsdesk
The Oncology Institute (NASDAQ:TOI) reported Q2 losses of $(0.19) per share, missing the analyst consensus estimate of $(0.17) by 11.76%. This is a 216.67% increase in losses from the same period last year. However, the company reported quarterly sales of $80.22 million, beating the analyst consensus estimate of $73.79 million by 8.72%, a 31.69% increase from last year.
August 08, 2023 | 9:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The Oncology Institute reported higher than expected losses for Q2, but also reported higher than expected sales. This mixed result could lead to uncertainty in the market.
The Oncology Institute reported a larger loss than expected, which could negatively impact the stock price. However, the company also reported higher than expected sales, which could have a positive impact. The mixed results make the short term impact on the stock price uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100